Angiogenic and immune predictors of neoadjuvant axitinib response in renal cell carcinoma with venous tumour thrombus

Abstract Venous tumour thrombus (VTT), where the primary tumour invades the renal vein and inferior vena cava, affects 10–15% of renal cell carcinoma (RCC) patients. Curative surgery for VTT is high-risk, but neoadjuvant therapy may improve outcomes. The NAXIVA trial demonstrated a 35% VTT response...

Descripció completa

Dades bibliogràfiques

Autors principals:	Rebecca Wray, Hania Paverd, Ines Machado, Johanna Barbieri, Farhana Easita, Abigail R. Edwards, Ferdia A. Gallagher, Iosif A. Mendichovszky, Thomas J. Mitchell, Maike de la Roche, Jacqueline D. Shields, Stephan Ursprung, Lauren Wallis, Anne Y. Warren, Sarah J. Welsh, Mireia Crispin-Ortuzar, Grant D. Stewart, James O. Jones, On behalf of the NAXIVA Study Group
Format:	Artigo
Idioma:	Inglês
Publicat:	Nature Portfolio 2025-04-01
Col·lecció:	Nature Communications
Accés en línia:	https://doi.org/10.1038/s41467-025-58436-8
Etiquetes:	Afegir etiqueta Sense etiquetes, Sigues el primer a etiquetar aquest registre!